As successful examples of targeting intracellular inhibiting proteins in the context of cancer immunotherapy, we can mention recently adapted for clinical trials CISH, targeting PLC-γ1 and HPK-1, targeting SLP-769,22,53. This evidence concerns the gene PLCG1 and cancer.